Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/12/2025 | $30.00 | Overweight → Neutral | Analyst |
| 2/4/2025 | $66.00 → $36.00 | Overweight → Neutral | Piper Sandler |
| 11/22/2024 | $55.00 | Equal Weight | Wells Fargo |
| 3/5/2024 | $60.00 | Overweight | JP Morgan |
| 11/17/2023 | $63.00 | Neutral | BofA Securities |
| 7/25/2023 | $70.00 | Buy | Jefferies |
| 10/21/2022 | $36.00 | Buy | Jefferies |
| 7/29/2022 | $44.00 | Overweight | CapitalOne |
Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling
Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling
Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling